Eventide Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $15.2M | Hold |
|
|||||
|
2023
Q2 | $12.7M | Hold |
|
|||||
|
2023
Q1 | $13.7M | Hold |
|
|||||
|
2022
Q4 | $16.1M | Sell |
|
|||||
|
2022
Q3 | $25M | Hold |
|
|||||
|
2022
Q2 | $22.9M | Hold |
|
|||||
|
2022
Q1 | $22M | Hold |
|
|||||
|
2021
Q4 | $20M | Hold |
|
|||||
|
2021
Q3 | $22.5M | Hold |
|
|||||
|
2021
Q2 | $22.9M | Sell |
|
|||||
|
2021
Q1 | $46.1M | Buy |
|
|||||
|
2020
Q4 | $33.8M | Sell |
|
|||||
|
2020
Q3 | $34.6M | Buy |
|
|||||
|
2020
Q2 | $43.7M | Buy |
|
|||||
|
2020
Q1 | $30.6M | Hold |
|
|||||
|
2019
Q4 | $37.9M | Hold |
|
|||||
|
2019
Q3 | $31.8M | Hold |
|
|||||
|
2019
Q2 | $29.8M | Buy |
|
|||||
|
2019
Q1 | $23.8M | Buy |
|
|||||
|
2018
Q4 | $11.1M | Hold |
|
|||||
|
2018
Q3 | $19.2M | Hold |
|
|||||
|
2018
Q2 | $15.3M | Hold |
|
|||||
|
2018
Q1 | $12.9M | Hold |
|
|||||
|
2017
Q4 | $12.1M | Buy |
|
|||||
|
2017
Q3 | $7.66M | Hold |
|
|||||
|
2017
Q2 | $5.75M | Hold |
|
|||||
|
2017
Q1 | $5.41M | Hold |
|
|||||
|
2016
Q4 | $4.84M | Hold |
|
|||||
|
2016
Q3 | $6.33M | Hold |
|
|||||
|
2016
Q2 | $5.68M | Hold |
|
|||||
|
2016
Q1 | $4.94M | Hold |
|
|||||
|
2015
Q4 | $7.07M | Sell |
|
|||||
|
2015
Q3 | $9.79M | Buy |
|
|||||
|
2015
Q2 | $7.23M | Buy |
|
|||||
|
2015
Q1 | $5.47M | Buy |
|
|||||
|
2014
Q4 | $2.51M | Buy |
|
|||||
|
2014
Q3 | $1.51M | Hold |
|
|||||
|
2014
Q2 | $1.43M | Buy |
|
|||||
|
2014
Q1 | $1.41M | Buy |
|
|||||
|
2013
Q4 | $360K | Buy |
|